Eisai Co., Ltd.｜A human health care company

Certificate of Appreciation from National Department of Health of Papua New Guinea

Eisai's Support towards COVID-19
Eisai's Statement of Commitment for Carbon Neutrality by 2040

Medium- to long-term goals to achieve carbon neutrality
Video Library

Videos of Eisai's Activities Including Initiatives for Improving Access to Medicines
Lymphatic Filariasis Elimination Activities in Kenya

Support for MDA and Provision of Water Tanks

News Release
Latest News
Information

January 20, 2022

Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) in Advanced Endometrial Carcinoma Published in the New England Journal of Medicine
January 19, 2022

EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE SIXTH TIME
HIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY
January 19, 2022

FIRST SUBJECT ENROLLED IN PHASE II/III STUDY OF EISAI’S ANTI-MTBR TAU ANTIBODY E2814 FOR DOMINANTLY INHERITED ALZHEIMER'S DISEASE (DIAD), CONDUCTED BY DIAN-TU
EISAI’S ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY LECANEMAB SELECTED AS THE BACKGROUND THERAPY FOR THE TAU NEXGEN STUDY
January 17, 2022

EISAI TO PRESENT ABSTRACTS ON LENVATINIB AT 2022 ASCO GASTROINTESTINAL CANCERS SYMPOSIUM
January 13, 2022

Eisai’s Statement on the Draft National Coverage Determination (NCD) for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease

November 24, 2021

Statement on JAMA Neurology Publication about Amyloid-Related Imaging Abnormalities in Two Phase 3 Studies Evaluating Aducanumab in Early Alzheimer’s Disease
September 22, 2021

EISAI ITALY AWARDED HIGHEST CLASSIFICATION AT SIXTH ANNUAL WELFARE INDEX PMI* IN ITALY
April 19, 2021

Eisai formulates the action plan “Diversity & Inclusion 2021”
December 3, 2020

EISAI ITALY AWARDED HIGHEST CLASSIFICATION AT FIFTH ANNUAL WELFARE INDEX PMI* IN ITALY
October 28, 2020

INTERNATIONAL NONPROPRIETARY NAME FOR ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY BAN2401 DECIDED AS LECANEMAB

Eisai at a Glance

Eisai Group Worldwide

About Eisai

About Eisai TOP

Our pursuit of human health care (hhc)

Eisai's hhc Philosophy

Eisai's hhc Philosophy TOP

Investors

Sustainability

Making our medicines available to those who need them

29 countries 2.05 billion tablets

Number of countries supplied with lymphatic filariasis treatment
and volume supplied (as of December 2021)

Eisai is promoting initiatives for improving access to medicines to contribute to people in developing and emerging countries

Sustainability TOP